Research Frontiers Incorporated — Q1 2012 Form 10-Q Summary
Business Context and Reporting Period
Research Frontiers develops and licenses suspended particle device technology that controls the flow of light in glass and plastic products. Applications include architectural, automotive, marine, aerospace, appliance, eyewear, and display products. The company operates as a single business segment and primarily funds operations through cash reserves, investments, licensing fees, and royalties.
This filing covers the three months ended March 31, 2012, compared with the three months ended March 31, 2011. The financial statements are unaudited. As of May 7, 2012, 18,907,555 common shares were outstanding.
Financial Metrics
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Fee income | $482,578 | $144,441 | +$338,137 |
| Operating expenses | $1,439,393 | $1,325,690 | +$113,703 |
| Research and development | $477,738 | $411,971 | +$65,767 |
| Operating loss | $(1,434,553) | $(1,593,220) | Improved by $158,667 |
| Net investment income | $17,817 | $3,939 | +$13,878 |
| Income tax benefit | $613,397 | — | +$613,397 |
| Net loss | $(803,339) | $(1,589,281) | Loss reduced by $785,942 |
| Basic and diluted loss per share | $(0.04) | $(0.09) | Improved by $0.05 |
| Net cash used in operating activities | $(791,567) | $(668,448) | Use increased by $123,119 |
Fee income increased approximately 234%. The operating loss represented approximately 297% of fee income in Q1 2012, compared with approximately 1,103% in Q1 2011. The company remained loss-making and has not generated sufficient licensee revenue to fund operations.
Cash and cash equivalents were $1.832 million at March 31, 2012, compared with $2.403 million at December 31, 2011. Short-term investments were $1.258 million, bringing cash and short-term investments to approximately $3.089 million. Working capital was $3.669 million, and shareholders’ equity was $3.768 million.
Total liabilities were $556,080, consisting of accounts payable, deferred revenue, and accrued expenses. The filing does not report outstanding borrowings or debt.
Net cash used in operations was $791,567. Investing activities provided $219,947, primarily from the $224,903 repayment of principal and accrued interest on the SPD Control Systems note. Financing activities provided no cash in Q1 2012. Stock-based compensation totaled $463,881 and represented a significant non-cash expense.
Material Changes Versus the Prior Comparable Period
- Fee income rose primarily because automotive product sales by one licensee exceeded minimum annual royalty levels by $237,128.
- Four licensees accounted for approximately 69%, 5%, 5%, and 4% of Q1 2012 fee income, indicating substantial customer concentration. In Q1 2011, the five largest licensees accounted for approximately 17%, 17%, 16%, 11%, and 9%.
- Operating expenses increased due mainly to higher payroll and professional fees, partly offset by lower marketing and public relations costs.
- Research and development spending increased because of higher payroll, non-cash compensation, and material costs.
- The net loss improved substantially, but the improvement was significantly assisted by a $613,397 state research and development refundable tax-credit benefit rather than recurring operating profitability.
- Cash declined by $571,620 during the quarter, primarily because of operating cash usage.
- Deferred revenue increased to $187,500 from $25,000 at December 31, 2011, reflecting fees received before the related revenue was earned.
- Shares outstanding increased from 18,544,355 at December 31, 2011 to 18,907,555 at March 31, 2012, primarily reflecting restricted stock grants.
Guidance, Outlook, Risks, and Unusual Items
Management stated that, based on existing spending levels, cash reserves, and budgeted revenues, the company does not expect to require additional funding until the third quarter of 2013. This expectation is subject to operating expenditures, research and development needs, market and technology developments, patent costs, licensee additions, and changes in existing licensee relationships.
Management cautioned that additional financing may become necessary and may not be available on acceptable terms. Long-term success and positive cash flow depend on commercialization of products using the company’s technology by licensees and the resulting continuing royalty payments.
The $613,397 tax benefit relates to refundable state research and development credits for prior years. The company received $448,297 in April 2012 and expected to collect an additional $165,100. The company does not expect additional credits for subsequent years.
The company has significant exposure to licensee concentration, timing of product commercialization, royalty collection delays, technological and competitive developments, patent expenditures, and continued cash burn. Deferred tax assets remain fully reserved because management determined that realization was not more likely than not.
The filing contains an apparent inconsistency: the MD&A text refers to a Q1 2011 net loss of $1,598,281 and loss per share of $0.9, while the consolidated statements report a net loss of $1,589,281 and loss per share of $0.09. The financial statements should be treated as the primary reported values pending verification.
Management concluded that disclosure controls and procedures were effective as of March 31, 2012, and reported no material changes in internal control over financial reporting.
Important Facts for Investors to Verify
- Whether the increase in fee income, particularly the automotive-related royalty increase, is recurring or reflects a one-time or temporary sales level.
- The identity, financial condition, and commercial progress of the licensees contributing the majority of fee income.
- The sustainability of cash resources given quarterly operating cash usage of $791,567 and the company’s continuing operating losses.
- The timing and collectability of the remaining $165,100 state research and development credit.
- The accuracy of the prior-period net-loss and loss-per-share figures cited inconsistently in the MD&A.
- The status and commercialization prospects of SPD products across automotive, architectural, aerospace, and other markets.
- Potential future dilution from restricted stock, options, warrants, and other equity-based compensation arrangements.
- Whether the company can maintain operations without external financing if licensee royalties or budgeted revenues are lower than expected.